Maria Teresa Baltazar

Maria Teresa Baltazar

Auto-generated profile, based on publicly available information

Maria Teresa Baltazar

Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire, Mk44 1LQ, UK

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2020 in Toxicological Sciences
Verified
Journal Article
Open access
MBMaria T Baltazar
Maria T Baltazar
SCSophie Cable
Sophie Cable
PCPaul L Carmichael
Paul L Carmichael
RCRichard Cubberley
Richard Cubberley
TCTom Cull
Tom Cull
CWCarl Westmoreland
Carl Westmoreland
Next-Generation Risk Assessment is defined as an exposure-led, hypothesis-driven risk assessment approach that integrates new approach methodologies (NAMs) to assure safety without the use of animal testing. These principles were applied to a hypothetical safety assessment of 0.1% coumarin in face cream and body lotion. For the purpose of evaluating the use of NAMs, existing animal and human data on coumarin were excluded. Internal concentrations (plasma Cmax) were estimated using a physiologically based kinetic model for dermally applied coumarin. Systemic toxicity was assessed using a battery of in vitro NAMs to identify points of departure (PoDs) for a variety of biological effects such as receptor-mediated and immunomodulatory effects (Eurofins SafetyScreen44 and BioMap Diversity 8 Panel, respectively), and general bioactivity (ToxCast data, an in vitro cell stress panel and high-throughput transcriptomics). In addition, in silico alerts for genotoxicity were followed up with the ToxTracker tool. The PoDs from the in vitro assays were plotted against the calculated in vivo exposure to calculate a margin of safety with associated uncertainty. The predicted Cmax values for face cream and body lotion were lower than all PoDs with margin of safety higher than 100. Furthermore, coumarin was not genotoxic, did not bind to any of the 44 receptors tested and did not show any immunomodulatory effects at consumer-relevant exposures. In conclusion, this case study demonstrated the value of integrating exposure science, computational modeling and in vitro bioactivity data, to reach a safety decision without animal data.

17 March 2022 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Closed access
NGN. Gilmour
N. Gilmour
JRJ. Reynolds
J. Reynolds
KPK. Przybylak
K. Przybylak
MAM. Aleksic
M. Aleksic
NAN. Aptula
N. Aptula
GMG. Maxwell
G. Maxwell

1 December 2021 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Open access
GRG. Reynolds
G. Reynolds
JRJ. Reynolds
J. Reynolds
NGN. Gilmour
N. Gilmour
RCR. Cubberley
R. Cubberley
SSS. Spriggs
S. Spriggs
MBM.T. Baltazar
M.T. Baltazar
Next generation Risk Assessment (NGRA) is an exposure-led, hypothesis-driven approach which integrates new approach methodologies (NAMs) to assure safety without generating animal data. This hypothetical skin allergy risk assessment of two consumer products - face cream containing 0.1% coumarin and deodorant containing 1% coumarin - demonstrates the application of our skin allergy NGRA framework which incorporates our Skin Allergy Risk Assessment (SARA) Model. SARA uses Bayesian statistics to provide a human relevant point of departure and risk metric for a given chemical exposure based upon input data that can include both NAMs and historical in vivo studies. Regardless of whether NAM or in vivo inputs were used, the model predicted that the face cream and deodorant exposures were low and high risk respectively. Using only NAM data resulted in a minor underestimation of risk relative to in vivo. Coumarin is a predicted pro-hapten and consequently, when applying this mechanistic understanding to the selection of NAMs the discordance in relative risk could be minimized. This case study demonstrates how integrating a computational model and generating bespoke NAM data in a weight of evidence framework can build confidence in safety decision making.

12 July 2022 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Open access
JRJ. Reynolds
J. Reynolds
NGN. Gilmour
N. Gilmour
MBM.T. Baltazar
M.T. Baltazar
GRG. Reynolds
G. Reynolds
SWS. Windebank
S. Windebank
GMG. Maxwell
G. Maxwell
Our aim is to develop and apply next generation approaches to skin allergy risk assessment that do not require new animal test data and better quantify uncertainties. Quantitative risk assessment for skin sensitisation uses safety assessment factors to extrapolate from the point of departure to an acceptable human exposure level. It is currently unclear whether these safety assessment factors are appropriate when using non-animal test data to derive a point-of departure. Our skin allergy risk assessment model Defined Approach uses Bayesian statistics to infer a human-relevant metric of sensitiser potency with explicit quantification of uncertainty, using any combination of human repeat insult patch test, local lymph node assay, direct peptide reactivity assay, KeratinoSens™, h-CLAT or U-SENS™ data. Here we describe the incorporation of benchmark exposures pertaining to use of consumer products with clinical data supporting a high/low risk categorisation for skin sensitisation. Margins-of-exposure (potency estimate to consumer exposure level ratio) are regressed against the benchmark risk classifications, enabling derivation of a risk metric defined as the probability that an exposure is low risk. This approach circumvents the use of safety assessment factors and provides a simple and transparent mechanism whereby clinical experience can directly feed-back into risk assessment decisions.

21 February 2025 in Frontiers in Toxicology
Verified
Journal Article
Open access
PDF file
RÁRenato Ivan de Ávila
Renato Ivan de Ávila
IMIris Müller
Iris Müller
HBHugh Barlow
Hugh Barlow
AMAlistair Mark Middleton
Alistair Mark Middleton
MTMathura Theiventhran
Mathura Theiventhran
MBMaria Teresa Baltazar
Maria Teresa Baltazar
Introduction: This work evaluated a non-animal toolbox to be used within a next-generation risk assessment (NGRA) framework to assess chemical-induced lung effects using human upper and lower respiratory tract models, namely MucilAir™-HF and EpiAlveolar™ systems, respectively.Methods: A 12-day substance repeated exposure scheme was established to explore potential lung effects through analysis of bioactivity readouts from the tissue integrity and functionality, cytokine/chemokine secretion, and transcriptomics.Results: Eleven benchmark chemicals were tested, including inhaled materials and drugs that may cause lung toxicity following systemic exposure, covering 14 human exposure scenarios classified as low- or high-risk based on historical safety decisions. For calculation of bioactivity exposure ratios (BERs), obtained chemical-induced bioactivity data were used to derive in vitro points of departures (PoDs) using a nonlinear state space model. PoDs were then combined with human exposure estimates, i.e., predicted lung deposition for benchmark inhaled materials using multiple path particle dosimetry (MPPD) exposure computational modeling or literature maximum plasma concentration (Cmax) for systemically available benchmark drugs.Discussion: In general, PoDs occurred at higher concentrations than the corresponding human exposure values for the majority of the low-risk chemical-exposure scenarios. For all the high-risk chemical-exposure scenarios, there was a clear overlap between the PoDs and lung deposited mass and Cmax for the benchmark inhaled materials and therapeutic drugs, respectively. Our findings suggest that combining computational and in vitro new approach methodologies (NAMs) informed by adverse outcome pathways (AOPs) associated with pulmonary toxicity can provide relevant biological coverage for chemical lung safety assessment.

1 January 2025 in ALTEX
Verified
Journal Article
Open access
PDF file
MBMaria T. Baltazar
Maria T. Baltazar
SCSophie Cable
Sophie Cable
RCRichard Cubberley
Richard Cubberley
NHNicola J. Hewitt
Nicola J. Hewitt
JHJade Houghton
Jade Houghton
MDMatthew P. Dent
Matthew P. Dent
A next generation risk assessment was carried out to evaluate the safety of benzophenone-4 (BP-4), a UV filter present at 5% in a body lotion, to compare a non-animal approach with a traditional safety assessment based on historical animal data. Exposure characterization indicated that BP-4 is poorly absorbed through the skin, poorly metabolized by the liver, a substrate of influx and efflux transporters, and excreted by the kidney. The resulting physiologically-based kinetic model predicted an upper bound (95th percentile) plasma Cmax of 1.27 µM, and liver and kidney concentrations of 0.32 µM and 0.44µM, respectively. To characterize bioactivity, in silico and in vitro new approach methodologies were used. Points of departure (PoDs) were derived from four bioactivity platforms, including in vitro pharmacological profiling, CALUX assays, high-throughput transcriptomics, and a cell stress panel. By dividing the in vitro PoDs (PoDNAM) from these assays by the 95th percentile plasma Cmax value, so-called bioactivity:exposure ratios (BERs) were calculated. The lowest PoD was from a single gene expression change, and the highest PoD from phenotypic biomarkers using a primary renal cell model. Most BERs were above 11, except for those from gene-level PoDNAM in HepG2 and MCF-7 cells, which were 3.3 and 4.3. These lowest PoDNAMs are linked to gene transcription changes and are likely indicative of adaptive biological activity rather than adverse health effects. This work demonstrates the usefulness of next generation risk assessment in addressing pressing relevant regulatory questions without using animals. Plain language summaryThis study on benzophenone-4 (BP-4) highlights the potential of modern, non-animal testing methods to provide comprehensive safety evaluations. By demonstrating that BP-4 is poorly absorbed through the skin and efficiently excreted by the kidneys, the research underscores the compound's low systemic exposure. The use of advanced in silico and in vitro techniques allowed for detailed bioactivity assessments, revealing that most biological responses occurred at levels higher than the predicted consumer exposure and were likely adaptive. This approach not only aligns with the 3Rs principle by reducing reliance on animal testing but also offers a more ethical and potentially faster pathway for regulatory safety assessments. The findings suggest that next-generation risk assessments can effectively address safety concerns while paving the way for broader acceptance and implementation of these innovative methods in the regulatory landscape.